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Abstract
Since their discovery in 1986, Ral (Ras-like) GTPases have emerged as critical regulators of
diverse cellular functions. Ral-selective guanine nucleotide exchange factors (RalGEFs) function
as downstream effectors of the Ras oncoprotein, and the RalGEF-Ral signaling network comprises
the third best characterized effector of Ras-dependent human oncogenesis. Because of this, Ral
GTPases as well as their effectors are being explored as possible therapeutic targets in the
treatment of RAS mutant cancer. The two Ral isoforms, RalA and RalB, interact with a variety of
downstream effectors and have been found to play key and distinct roles in both normal and
neoplastic cell physiology including regulation of vesicular trafficking, migration and invasion,
tumor formation, metastasis, and gene expression. In this review we provide an overview of Ral
biochemistry and biology, and we highlight recent discoveries.
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1. Introduction
Identified initially as Ras-like (Ral) proteins, the Ral small GTPases are members of the Ras
branch of the Ras superfamily of small GTPases [1]. RALA was identified initially using
oligonucleotide probes to identify RAS-related genes in a cDNA library established from
immortalized simian B-lymphocytes [2]. Three years later, using the simian RALA cDNA as
a probe, human RALA and a related RALB gene were identified from a human
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pheochromocytoma cDNA library [3]. Subsequently, single RAL orthologs were identified
in C. elegans (RAL-1) [4] and Drosophila (RalA) [5] (Fig. 1). Interestingly, although there
are well-conserved RAS orthologs in yeast, no RAL orthologs are present in S. cerevisiae or
S. pombe.
The three human RAS genes (HRAS, KRAS and NRAS) comprise one of the most frequently
mutated gene families in human cancers [6]. Consequently, they have been the subject of
intense research scrutiny and cancer drug discovery. Initially, the discovery of Ral proteins
simply added to a rapidly growing roster of proteins that now comprise a large superfamily
of >150 Ras-related small GTPases [1]. However, with discoveries that Ral GTPases are key
regulators of vesicular trafficking and are effectors of Ras oncoprotein-driven growth
transformation, Ral proteins stepped into the spotlight in 2003 to bask in their “15 minutes
of fame” [7]. Since those initial findings, more discoveries on the role of Ral in normal and
cancer cell physiology have ensured that their “fame” will last considerably more than 15
minutes. In this review, we summarize our current knowledge on Ral GTPases and we
highlight recent findings in Ral function.
2. Ral proteins
2.1. Ral protein structure
The highly related human RalA and RalB isoforms share 82% overall amino acid sequence
identity (Fig. 1A) and are members of the Ras branch of the Ras superfamily (Fig. 1B). They
share 46-51% sequence identity and domain architecture with Ras proteins [8]. However,
Ral proteins contain an N-terminal 11 amino acid extension not found in Ras, accounting for
the 11 residue shift in numbering compared with Ras residue numbering (Fig. 1C). This is
followed by the G domain, involved in GTP binding and hydrolysis, and the C-terminal
membrane targeting sequence. The majority of sequence divergence occurs within the C-
terminal hypervariable regions (50% shared identity) (Fig. 1C).
Like Ras, Ral proteins cycle between inactive GDP-bound and active GTP-bound states
(Fig. 2A). RalA and RalB share complete sequence identity in the switch I (SI) and II (SII)
sequences that change conformation during GDP-GTP cycling [8] (Fig. 2B). As described
below, SI and SII are involved in recognition by both regulators and effectors. The
conservation of SI and SII sequences in Drosophila and C. elegans Ral proteins support their
interaction with conserved regulators and effectors.
Similar to Ras, the intrinsic GDP-GTP exchange and GTP hydrolysis activities of Ral
GTPases are very weak, with each activity accelerated by Ral-selective guanine nucleotide
exchange factors (RalGEFs) and GTPase activating proteins (RalGAPs), respectively (Fig.
2A). RalGEFs stimulate guanine nucleotide exchange. With intracellular levels of GTP
approximately 10-fold higher than GDP, RalGEF stimulation favors formation of Ral-GTP.
Ral GTPase-activating proteins (RalGAPs) catalyze the hydrolysis of the bound GTP,
returning Ral to an inactive conformation. When bound to GTP, RalA and RalB can interact
with the same array of downstream effector proteins and mediate numerous cellular
processes.
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The first RalGEF identified, Ral guanine nucleotide dissociation stimulator (RalGDS) (Fig.
2B), was found by yeast two-hybrid screens performed in the early 1990s to identify Ras
effectors [9-11]. RalGDS was found to catalyze nucleotide exchange on both RalA and RalB
but not on other small GTPases including members of the Ras, Rho, and Rab families.
Subsequent yeast two-hybrid library screening studies using H-Ras, R-Ras, TC21/R-Ras2,
and Rit as baits identified three additional RalGEF proteins that were named Rgl (RalGDS-
like), Rgl2/Rlf, and Rgl3 [12-14] [15]. These RalGEFs contain a common domain
architecture including an N-terminal Ras exchanger motif (REM) domain followed by a
CDC25 homology domain (RasGEF) and a C-terminal Ras-association (RA) domain (Fig.
2A) [16]. The CDC25 homology domain shares sequence identity with the catalytic domains
of RasGEFs [17]. In addition to the three Ras isoforms, other Ras family small GTPases can
also bind and activate the RA domain-containing RalGEFs [18].
RalGPS1 and RalGPS2 (Ral GEF with PH domain and SH3-binding motif) comprise a
second distinct family of RalGEFs [19-21] (Fig. 2A). These two related proteins (63%
identity) contain an N-terminal CDC25 homology RasGEF but lack a REM and RA domain.
Instead, they contain a C-terminal pleckstrin homology (PH) domain. Additionally, they
possess is a central proline-rich sequence with PxxP motifs recognized by Src homology 3
(SH3) domain-containing proteins.
The absence of an RA domain uncouples these RalGEFs from direct association with Ras
family small GTPases. Instead, the PH domain has been shown to be sufficient for
membrane targeting and necessary for Ral activation [19]. The regulation of these RalGEFs
is poorly understood, but some evidence suggests that RalGPS2 plays a role in regulating the
actin cytoskeleton [21]. Interestingly, members of both RalGEF subclasses have been
implicated in cytokinesis [22].
Another RalGEF, now designated RGL4, was identified originally as a RalGDS-related
(Rgr) oncogene in a DMBA (7,12-dimethylbenz[α]anthracene)-induced rabbit squamous
cell carcinoma [23]. However, while RGL4 does contain a CDC25 homology domain, it
lacks a well-defined RA or PH domain (Fig. 2B). Furthermore, while the other RalGEFs
described above are highly selective activators of Ral, RGR has also been described to
activate other Ras family small GTPases [24].
2.3. RalGAPs
Although the existence of RalGAPs was first reported in 1991 [25], only recently has the
molecular identification of RalGAPs been achieved (Fig. 2C). Work done by Feig and
colleagues in the early 1990s detected and characterized RalGAP activity in brain and testes
cytosolic extracts, and the putative RalGAP activity was distinct in size from Ras or Rho
GAPs [25]. Subsequently, using a GTPase-deficient, persistently GTP-bound mutant of
RalA for affinity chromatography, two distinct RalGAP complexes were identified in brain
cytosol [26]. Each heterodimeric complex consists of a shared regulatory RalGAPβ subunit
and one of two related catalytic RalGAPα1 and α2 subunits (53% overall sequence identity)
(Figs. 2A,C). Independently, Saltiel and colleagues used a similar RalA affinity purification
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approach and identified RalGAPα2 (RGC2) and RalGAPβ (RGC1) as components of a Ral-
selective GAP [27].
RalGAPα1 (GARNL1/TULIP1) and RalGAPα2 (AS250; Akt substrate of 250 kDa) were
identified previously as proteins with sequence identity with the GAP catalytic domain of
TSC2 (also known as tuberin) [28, 29] (Fig. 2B) and distinct from the RasGAP catalytic
domain [17]. RalGAPα2 was also identified to form a complex with RalGAPβ (KIAA1219).
TSC2 is the catalytic subunit of a GAP selective for the Rheb small GTPases, another
member of the Ras branch of the Ras superfamily [1]. However, TSC2 alone is not sufficient
for RhebGAP activity and requires heterodimer formation with TSC1 (also known as
hamartin). Hence, the active RalGAPα/β complexes share both sequence and structural
similarities with the heterodimeric tuberous-sclerosis (TSC) complex [30]. Although
RalGAPβ lacks sequence similarity with Tsc1, it serves an analogous role in stabilizing
RalGAPα and is required for RalGAP activity. RalGAPβ is expressed ubiquitously, whereas
more variable expression profiles are seen for the two RalGAPα subunits. RalGAPs are
conserved in evolution, with orthologs of both subunits found in C. elegans and Drosophila
(Fig. 2B) [26, 31]. The RalGAPα GAP catalytic domains of C. elegans (HGAP-1) and
Drosophila (CG5521) share 37-39% and 58-59% sequence identity, respectively, with the
GAP catalytic domains of their human counterparts.
RalGAP accelerates the GTPase activity of both RalA and RalB but not for other small
GTPases tested (H-Ras, Rap1, Rheb, RhoA, Ran and Rab27) [26, 27, 31]. The RalGAPα
subunits share 53% overall sequence identity and 83% sequence identity in their GAP
domains (Figs. 2C,D). Additionally, RalGAPα2 is subject to insulin-stimulated
phosphorylation by the AKT serine/threonine kinase, analogous to a similar mechanism of
AKT regulation of TSC2 [32]. As with TSC2, AKT phosphorylation of RalGAPα2 impaired
the ability of the RalGAP complex to catalyze RalA GTP hydrolysis. This is not due to
altered intrinsic GAP activity but to a reduced RalA interaction with RalGAPα2.
3. Ral effectors
Like Ras and other small GTPases, Ral interacts with a number of effector proteins when
bound to GTP (Fig. 3). However, unlike with Ras, the Ral binding domains (RBD) lack
primary sequence identity. The best characterized Ral effectors are RalBP1/RLIP76 and the
Sec5 and Exo84 subunits of the octameric exocyst complex. The evolutionarily conserved
exocyst complex mediates the tethering of post-Golgi secretory vesicles to the plasma
membrane prior to exocytic fusion [33]. The exocyst subunits may also exist as monomers
or subcomplexes, and can possess non-exocyst functions. Ral interaction with each subunit
occurs in distinct subcellular locations, interacting with Sec5 at the plasma membrane and
with Exo84 with intracellular vesicles [34, 35]. Although RalA and RalB can interact with
the same set of effectors in vitro, as described below, the distinct biological functions of
RalA and RalB are mediated by differences in subcellular localization, leading to their
interaction with distinct subsets of effectors.
The structures of Ral in complex with the RBDs of these three effectors have been
determined. Whereas the Sec5 RBD interacts with SI alone [36], Exo84 [37] and RalBP1
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[38] RBD interaction involves both SI and SII [39]. Consistent with 100% conservation of
SI and SII residues, and residues involved with effector binding, where studied, RalA and
RalB interact with the same set of effectors in vitro.
3.1. RalBP1/RLIP76
The first Ral effector described, RalBP1 (Ral binding protein 1; also called RLIP76 or
RIP1), was identified in screens for proteins that bound preferentially to activated RalA
[40-42]. RalBP1 orthologs are found in Drosophila and C. elegans. RalBP1 contains a
RhoGAP catalytic domain that has activity for the Cdc42 and Rac small GTPases, members
of the Rho branch of the Ras superfamily [1]. Cdc42 stimulates filopodia formation whereas
Rac stimulates lamellipodia formation. Thus, RalBP1 provides a link between Ral and
modulation of the actin cytoskeleton changes that drive these cellular activities [40].
In additional to its RhoGAP domain, RalBP1 has additional functions (Fig. 3). Two ATP
binding motifs have been identified in RalBP1 and shown to be important for transport
function involving glutathione conjugates of electrophilic compounds [43, 44]. This
transport function may facilitate the cellular export of chemotherapeutic drugs and radiation-
induced oxidative damage byproducts [45]. RalBP1 overexpression has been found in a
spectrum of human cancers, and suppression of RalBP1 expression can impair tumorigenic
growth in vivo [46]. However, phenotypes attributed to RalBP1 do not necessarily implicate
their role in Ral signaling [47].
RalBP1 also functions as a scaffold and interacts with a spectrum of functionally distinct
proteins that regulate endocytosis and signal transduction (Fig. 3). The AP2 adaptor
complex, a regulator of clathrin-mediated endocytosis from the plasma membrane,
associates with the N-terminal region of RalBP1 [48]. The Eps homology (EH) domain-
containing proteins Reps1 and Reps2 (POB1) were identified as proteins that interacted with
the C-terminus of RalBP1 [49, 50]. These proteins are known to be important for receptor
tyrosine kinase-regulated endocytosis, with Reps1 interacting with Rab11-FIP2 and Reps2
binding Epsin and Eps15 [51, 52].
Another protein that associates with the RalBP1 C-terminus is cyclin B1 [53]. In turn, the
RalBP1-bound cyclin B1 complexes with Cdk1, with Cdk1 phosphorylation of Epsin
preventing endocytosis during mitosis. This activity was shown to be mediated by RalA
activation.
RalBP1 has been implicated as a key effector for several Ral-driven processes. In these
studies, the typical approach has been the utilization of mutants of Ral that are selectively
impaired in effector interaction. The D49N substitution impairs RalBP1 but not Sec5 or
Exo84 effector binding, whereas the D49E mutation has the opposite consequence [40, 54,
55]. For example, shRNA silencing analyses determined that RalB but not RalA was
required for invadopodia formation in pancreatic cancer cell lines [56]. RalB D49E but not
D49N could rescue loss of endogenous RalB and restore invadopodia formation, indicating
that RalBP1 was a critical effector for this RalB activity. This RalBP1 function was GAP-
independent but abolished by mutation of the ATP binding motifs [56].
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RalA was shown to utilize RalBP1 to regulate mitochondrial fission at mitosis [57].
Mitochondria exist as dynamic interconnected networks that are maintained through a
balance of fusion and fission. Fission facilitates equal distribution of mitochondria to
daughter cells during mitosis. Fission is controlled by the GTPase DRP1 on the outer
mitochondrial membrane. RalA was found to recruit RalBP1 to mitochondria, where
RalBP1 acts as a scaffold to facilitate cyclin B/Cdk1 phosphorylation of Drp1 to promote
mitochondrial fission. Suppression of either RalA or RalBP1 expression caused a loss of
mitochondrial fission at mitosis.
Recently, RalBP1 was shown to be necessary and sufficient for RalA-driven mislocalization
of the cyclin-dependent kinase inhibitor p27 KIP1, leading to inhibition of TGF-β–mediated
growth arrest in epithelial cells [58]. This function appeared to require an intact RhoGAP
domain.
3.2. The Sec5 and Exo84 subunits of the exocyst
The best-characterized Ral effectors are two components of the exocyst complex, Sec5 and
Exo84 [54, 55, 59]. The association of Ral with both Sec5 and Exo84 has been found to be
important in exocytosis. Ral regulates the subcellular localization of the exocyst through
mediating Sec5-paxillin association and the assembly of the octameric exocyst complex by
interacting with Sec5 and Exo84 [55, 60]. Ral interaction with Sec5 may also regulate
exocyst-independent functions.
Recent evidence suggests that Ral engages exocyst subunits to perform a variety of cellular
processes independent of their roles in exocytosis. White and colleagues found that the
association of RalB with Sec5 is critical in the innate immune response [61]. RalB binding
to Sec5 leads to an interaction of Sec5 with TBK1, a protein kinase known to regulate NF-
κB signaling. Intriguingly, TBK1 has recently been identified in siRNA screens as a
synthetic lethal partner of activated K-Ras [62], although a subsequent study failed to
support this relationship [63].
Recently, a mechanism where the integrin αvβ3 recruited a K-Ras-RalB complex to the
plasma membrane to activate TBK1 and NF-κB signaling was identified (Fig. 3) [64]. This
signaling mechanism regulated tumor initiation and growth.
The association of RalB with the exocyst has also been shown to regulate macroautophagy
[34]. When cells are grown in nutrient-rich conditions, RalB engages Sec5. Upon nutrient
starvation, RalB then engages Exo84 and the exocyst, leading to an upregulation of
autophagosome formation. This process is mediated through the assembly of the ULK1
serine/threonine kinase and Beclin1-VPS34 complexes on the exocyst. Autophagy has
emerged as a key component of Ras-driven transformation in a variety of cell types, perhaps
highlighting an underlying importance of Ras-RalGEF signaling in tumor cell autophagy.
3.3. Other effectors
One lesser-characterized Ral effector is phospholipase D1 (PLD1) [65, 66]. However, unlike
other effectors, the association with Ral is not GTP-dependent and instead the association is
with the N-terminal 11 amino acid extension (Fig. 1D). PLD1 is best known for its role in
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converting phosphotidylcholine to phosphatidic acid and choline in response to G-protein
coupled receptor (GPCR) stimulation. Recent evidence shows that RalA is necessary for the
PLD1-mediated stimulation of mTORC1 signaling [67]. Furthermore, the RalA-PLD1
interaction has been shown to promote proper p27 localization, thus allowing for proper
TGF-β signaling [58]. The interaction of both RalA and RalB with PLD1 has been shown to
be critical for HeLa cell cytokinesis [22].
Filamin is an important component of the actin cytoskeleton and is involved in actin
crosslinking and lamellipodia formation. The association of RalA with filamin was found to
be important for filopodia formation in Swiss-3T3 cells [68]. Additionally, RalA did not
induce filopodia in a human melanoma cell line that lacks expression of filamin.
Lastly, active RalA has been shown to engage the transcription factor ZONAB (zonula
occludens 1-associated nucleic acid binding protein) in a cell density dependent manner in
MDCK cells [69]. At high cell densities, RalA engages ZONAB, unlocking the transcription
of ZONAB targets, but it is unclear which genes are turned on [69]. While a direct role for
Ral association with these lesser-studied effectors has not been found in Ral-driven cancers,
their important roles in mitosis, motility, and gene regulation make them intriguing targets
as Ral studies progress.
4. Post-translational modification and regulation of Ral function
RalA and RalB exhibit the most significant sequence divergence in their C-terminal
membrane targeting sequences (50% identity) (Fig. 1C). This sequence divergence results in
their distinct subcellular localization that contributes to the functional differences described
for RalA and RalB by regulating effector utilization in vivo [56, 70-73]. Both isoforms can
be found at the plasma membrane as well as in endomembranes, with cell type differences
seen. In this section we summarize the role of posttranslational modifications that regulate
Ral subcellular localization.
4.1. CAAX modifications
Like the majority of Ras family small GTPases, RalA and RalB terminate in a CAAX (C =
cysteine, A = aliphatic amino acid; X = terminal amino acid) tetrapeptide motif (Fig. 4). The
CAAX motif signals for a series of posttranslational modifications that increase
hydrophobicity and promote membrane anchoring, where the terminal X residue determines
protein prenyltransferase specificity [74]. When X = S, A, Q, and M, the protein is
preferentially recognized by farnesyltransferase (FTase)-catalyzed addition of a C15
farnesyl isoprenoid lipid; when X = L or I, it signals for geranylgeranyltransferase type I
(GGTase-I)-catalyzed addition of a C20 geranylgeranyl isoprenoid.
For Ral, the initial step is catalyzed by covalent addition of geranylgeranyl to the cysteine
residue of the CAAX motif by cytosolic GGTase-I [75]. This is followed by endoproteolytic
removal of the AAX residues, catalyzed by endoplasmic reticulum-associated Ras
converting enzyme 1 (RCE1), and subsequent carboxymethylation of the now terminal
prenylated cysteine residue, catalyzed by isoprenylcysteine carboxyl methyltransferase
(ICMT).
Gentry et al. Page 7






















The CAAX-signaled modifications are critical for both RalA and RalB function. Mutation of
the cysteine residue to prevent all CAAX-signaled modifications disrupts Ral membrane
association and function [75]. Similarly, treatment with a pharmacologic inhibitor of
GGTase-I also disrupted Ral membrane association and signaling. Since inhibition of the
GGTase-I modification prevents all subsequent modifications, the role of the Rce1 and
ICMT catalyzed modifications in Ral function remain to be addressed.
Recently, the Ral CAAX motifs were identified as members of a distinct subset of CA1A2X
motifs where the A1 residue is a second cysteine residue (CCAX). CCAX motifs can
undergo an alternative modification pathway (Fig. 4). As shown for a Rho family small
GTPase (Cdc42), this motif can signal for dual lipid modification: prenylation followed by
covalent addition of a palmitate fatty acid [76]. For Cdc42, after the initial GGTase-I
catalyzed prenylation step, a Golgi-associated protein acetyltransferase (PAT) catalyzes
covalent addition of palmitate to the adjacent cysteine residue rather than the conventional
modification by Rce1 and ICMT. For Cdc42, this alternative modification prevented its
recognition by RhoGDI, a protein that masks the prenyl lipid and disrupts membrane
association, resulting in a cytosolic pool of Cdc42. Since there is no known RalGDI, the
consequences of this palmitate modification on Ral subcellular localization and membrane
association, and function, have not been determined.
4.2. Phosphorylation regulation of subcellular localization and effector interaction
An emerging theme in the regulation of small GTPases is reversible post-translational
modifications that dynamically regulate subcellular localization, thereby influencing effector
interaction and biological activity [77]. In particular, recent studies have highlighted protein
kinase-mediated phosphorylation of small GTPases in their C-terminal membrane-targeting
regions. For example, K-Ras4B phosphorylation by protein kinase C (PKC) on S181 in its
C-terminal membrane targeting sequence altered K-Ras4B subcellular localization [78].
Nonphosphorylated K-Ras4B was plasma membrane associated, whereas S181
phosphorylation K-Ras4B caused translocation to mitochondrial and endoplasmic reticulum
(ER) membranes. S181 is positioned within a polybasic amino acid stretch in K-Ras4B that
serves as a second signal that together with the CAAX modifications promote full plasma
membrane association. The negative charge caused by phosphorylation reduces the positive
charge of the polybasic stretch. The ER-associated K-Ras4B then associated with inositol
trisphosphate receptors (InsP3) on the ER in a Bcl-xL-dependent fashion, blocking the
ability of Bcl-xL to potentiate the InsP3 regulated flux of calcium from ER to mitochondria
that is required for respiration, inhibition of autophagy, and cell survival [79].
The Ral proteins are also regulated by similar mechanisms, with distinct protein kinases
phosphorylating serine residues distinct for the C-termini of RalA and RalB (Fig. 4).
Aurora-A kinase and protein kinase A (PKA) have been found to phosphorylate RalA on
S194 [80, 81] and protein phosphatase 2A dephosphorylates RalA at S194 as well as S183
[82]. Counter and colleagues showed that phosphorylation of RalA on S194 was critical for
RalA to promote the anchorage-independent growth in vitro and tumorigenic growth in nude
mice of pancreatic ductal adenocarcinoma (PDAC) cell lines [71]. This phosphorylation
event dramatically altered RalA subcellular localization from the plasma membrane to
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internal membranes, where it had an enhanced interaction with RalBP1. More recently,
Aurora-A phosphorylation of RalA has been found to promote RalA translocation to the
outer face of mitochondria, where it then recruits RalBP1 to stimulate mitochondrial fission
[57].
Studies by our lab and others have found that RalB is similarly regulated by PKCα
phosphorylation of S198 in the C-terminal membrane targeting sequence [72, 81]. In one
study, it was found that S198 phosphorylation caused RalB translocation from the plasma
membrane to endocytic vesicles [72]. Associated with this change in subcellular localization
was a switch in effector utilization. Whereas unphosphorylated RalA preferentially
associated with Sec5, S198 phosphorylation caused preferential association with RalBP1.
Phosphorylation of RalB S198 was necessary for proper exocytic vesicle trafficking and
fusion at the plasma membrane, with delivery of surface alpha-5 integrin being regulated by
dynamic RalB phosphorylation. Independently, Theodorescu and colleagues found that
phosphorylation of RalB S198 was critical in regulating the ability of RalB to promote the
metastatic growth of bladder cancer cells in a nude mouse model [81].
4.3. Ubiquitination
In the past few years, regulation of small GTPases by ubiquitination has gained recognition
[77]. For example, monoubiquitination of K-Ras on K147 reduces GAP sensitivity, thus
allowing K-Ras to remain active and signaling in the absence of upstream input [83].
Ubiquitination of the Ral proteins has also been shown to influence their activity and
function. Regulation of the ubiquitination of RalA modulated RalA activity as well as lipid
raft exposure [84]. Furthermore, ubiquitination of RalB promoted binding to Sec5 to
regulate innate immunity, whereas deubiquitination allowed for binding to Exo84 and
subsequent induction of autophagy [85].
5. Ral function in invertebrates – lessons learned from worms and flies
The conservation of Ral GTPases, their regulators, and effectors in Drosophila melanogaster
and C. elegans has allowed genetic dissection of Ral function. Consistent with the probable
double genome duplication and subsequent winnowing of vertebrate relative to invertebrate
genomes [86], in Drosophila and C. elegans there exist single genes for most Ras and Ral
signaling components. For example, Drosophila and C. elegans each harbor single Ral
GTPase (two in mammals) and RalGEF/RalGDS (four in mammals; Drosophila but not C.
elegans encodes a RalGPS ortholog), RalGAP α and β (two and one in mammals,
respectively) genes. This trend is consistent with reduced gene complexity of other
invertebrate Ras system signaling genes, with three mammalian Ras, three Raf, and four
type I PI3K catalytic subunit encoding genes [87]. Generally, functional similarity between
an invertebrate protein and a specific vertebrate isoform is difficult to extrapolate, largely
because biological assays usually differ between invertebrates and mammals. But this
difference also highlights the benefit of invertebrate studies, since they provide unique in
vivo perspectives that complement mammalian studies. All key Ral effectors are conserved
in C. elegans and Drosophila but TBK1, which is not encoded in the C. elegans genome.
Below, we summarize findings from studies on C. elegans and Drosophila Ral signaling.
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5.1. Toggling Ras between Raf and RalGEF regulation
Since RalGEFs and other Ras effectors are widely expressed, how Ras effector utilization is
regulated has been an unresolved issue. The C. elegans vulva is patterned by epidermal
growth factor (EGF) activation of Ras (LET-60) and the Raf-MEK-ERK MAP kinase
cascade to control 1° fate, and presumptive 1° cells secrete DSL Notch ligands to induce 2°
fate in neighboring cells. Furthermore, a spatial EGF gradient, in addition to inducing 1°
fate, contributes to 2° fate via an unknown pathway. 1° and 2° cell fates are antagonistic and
mutually exclusive. Reiner and colleagues found that in addition to its canonical effector,
Raf, vulval Ras utilized RalGEF-Ral 2°-promoting activity to antagonize Ras-Raf 1°-
promoting activity, and that Ral promoter activity was excluded from presumptive 1° cells,
thus blocking inappropriate Ral activation in 1° cells [88] (Fig. 5). Consistent with its
restricted expression pattern, they found that Ras-RalGEF-Ral mediated the 2°-promoting
activity of the EGF gradient. These findings delineated a Ras effector-switching mechanism
whereby cell position within the morphogen gradient dictates that LET-60/Ras effector
usage switched from Raf to RalGEF to promote 2° instead of 1° fate. This dynamic
developmental switching in effector use may reflect diversity in tumorigenic processes that
results in heterogeneity of effector predominance in tumors [89]. Other mechanisms that
control Ras effector utilization will likely exist.
5.2. Ral and innate immunity
A recent study in mammalian cells showed that RalA mediates nuclear translocation and
activation of FOXO in response to reactive oxygen species (ROS) by activating a JNK
cascade scaffolded by JIP1, and that in C. elegans RAL-1 and JIP-1 mediate DAF-16/FOXO
ROS-dependent nuclear translocation [90]. Additionally, transportin-1 mediates ROS-
dependent nuclear translocation of DAF-16/FOXO in both mammals and C. elegans [91]. C.
elegans harbors a single FOXO gene, daf-16, compared to four mammalian genes. These
observations suggest that Ral-mediated stress response to ROS is conserved across
evolution.
As noted above, mammalian RalB harnesses the TBK1 IκB kinase family member for tumor
cell survival. These results are echoed in Drosophila, where Sec5 or Ral haploinsufficiency
reduces anti-fungal response [61]. The absence of TBK1 and other IκB–related proteins in
the worm genome may reflect the absence of NF-κB in the worm genome and attendant
differences in innate immunity [92].
5.3. Fly insights into Ral signaling partners
Yeast two-hybrid interaction studies in Drosophila identified the Ral effectors Sec5 and
RalBP1/RLIP, and RalBP1/RLIP binds with known partner REPS1 [93]. Upstream of Ral,
both fly Ras and fly Rap bind RalGEF in yeast two-hybrid assays, consistent with their
identical core effector binding regions. However, in mammalian systems Ras and Rap1 are
localized to mostly non-overlapping subcellular compartments, and it is expected that they
encounter distinct sets of effectors [94, 95]. Overexpression studies with the two splice
variants of the fly RalGEF suggest that one alternative isoform, differing in N-terminal
sequence, harbors Ral-independent functions. This putative GEF-independent function of
RalGEF may correspond to putative N-terminally encoded GEF-independent functions of
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mammalian RalGDS, where RalGDS is thought to scaffold PDK and Akt, thus potentiating
Akt output in certain circumstances [96, 97]. Genetic analyses, mostly using ectopically
expressed constructs, implicates the Rap1 small GTPase, rather than Ras, as a putative
activator of RalGEF. However, these results are also consistent with Rap1 functioning in
parallel, and illustrate the potential complexities of dominant-negative mutations as
experimental tools for small GTPases, as well as the difficulties of analyzing the functions
of essential genes in vivo [98]. The Ras, Rap1 and Ral small GTPases act in multiple
developmental events during Drosophila development, so there is ample opportunity to
study their functions further.
Drosophila genetic analysis of a sensory organ apoptotic event, coupled with yeast two-
hybrid gene discovery and mammalian biochemical experiments, identified an interesting
and otherwise unidentified Ral effector cascade [99]. Ral signals through Sec5 of the
exocyst complex, which in turn interacts with the Msn MAP4 kinase in flies and humans.
Msn is thought to signal through a basket/JNK MAP kinase cascade in flies, and its ortholog
HGK signals through a JNK MAP kinase cascade in human cells. The fly Msn and human
HGK proteins are members of the CNH domain-containing MAP4 kinases, which contain
ancient Ste20-like kinase domains thought to activate JNK and p38 MAP kinases cascades.
Drosophila encodes two family members (Msn and Hpy), C. elegans encodes two family
members (MIG-15 and GCK-2), and mammals contain eight distinct genes encoding CNH
domain-containing MAP4 kinases, with four corresponding to each invertebrate subgroup
[100]. This relatively under-investigated group of kinases may represent a new and
druggable Ral signaling output.
5.4. RalGAPs connect Ral with the mTORC1 signaling network
An unexpected crosstalk between the Ral and mTOR signaling networks was identified
through the sequence relationship shared with the GAPs that control each network. mTOR
signaling regulates a spectrum of major cellular processes and is implicated in cancer and
other pathologic conditions [30]. Despite the sequence identity with TSC2 (26-27% identity
in RalGAP domains) (Fig. 2D), RalGAPs do not exhibit GAP activity for Rheb in vitro or in
vivo [31]. Nevertheless, the unexpected observation that C. elegans possesses orthologs for
the Rheb and Ral GTPases and for RalGAPα/β, but not Tsc1/2, led to the discovery of an
unexpected signaling interplay between Ral and Rheb signaling [31]. It was determined that
C. elegans RalGAP loss caused decreased lifespan, consistent with a Tsc-like function.
Additionally, RalGAP suppression in mammalian cells caused RalB-selective activation and
Sec5- and exocyst-dependent engagement of the mTORC1 complex and suppression of
autophagy (Fig. 3). Surprisingly, it was also found that Tsc1-Tsc2 loss activated RalA/B
independently of Rheb-mTOR signaling. Finally, RalGAP suppression caused mTORC1-
dependent pancreatic tumor cell invasion. These findings identify an unexpected crosstalk
and integration of the Ral and mTORC1 signaling networks.
Interestingly, as noted above mammalian RalB also activates autophagy, an activity
supported by Drosophila experiments [34]. Since TORC1 inhibits autophagy [101, 102], the
observations that RalB both promotes and inhibits autophagy are potentially contradictory.
However, RalB-TORC1 signaling occurs at the plasma membrane while RalB-
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autophagosome signaling occurs at the lysosome/autophagolysosome. The aforementioned
observations of phosphorylation-dependent subcellular trafficking and effector switching of
K-Ras [78] and RalA [82] , raise the possibility that RalB can orchestrate seemingly
antagonistic signaling outcomes under different conditions and in different cellular
compartments.
6. Ral and cancer
Since RalGEFs participate in downstream signaling from activated Ras proteins, it was
initially speculated that Ral protein activation may contribute to Ras-driven cellular
transformation. However, when explored initially in NIH 3T3 mouse fibroblasts, a critical
and significant role for Ral GTPases in Ras-driven cancer seemed unlikely [103, 104].
However, when Counter and colleagues explored the role of Ral in Ras-mediated growth
transformation of immortalized human astrocytes, fibroblast or epithelial cells, a more
significant role for Ral GTPases as effectors of Ras in human cancer was observed,
suggesting species differences in the effectors that are important in Ras oncogene function
[105].
That Ral GTPases serve critical roles in human cancer cell growth gained greater traction
when White and colleagues found that RalB was critical for tumor but not normal cells for
survival, while RalA was necessary for the anchorage-independent growth of cancer cells
[106]. Importantly, this also marked the first time RalA and RalB were found to have non-
overlapping functions. Since these key studies, a major theme of Ral proteins is their
significant and often divergent roles in numerous cancer types. In the following section we
review some of the key findings made with regards to the role of the two Ral isoforms as
drivers in different human cancers. Since the RA domain-containing RalGEFs can be
activated by other Ras family small GTPases, as well as by non-Ras mechanisms, and since
some RalGEFs are regulated by non-Ras mechanisms, an involvement of Ral in cancers
where RAS mutations are not common is not surprising.
6.1. Bladder carcinoma
Evaluation of a panel of human bladder cancer cell lines found preferentially increased
levels of activated RalA and RalB in RAS-mutant [107] or invasive cell lines [108]. Using
RNAi or ectopic expression of activated Ral mutants, Theodorescu and colleagues found
that RalA and RalB played antagonistic roles in the migratory activity of the KRAS-mutant
UM-UC-3 bladder cancer cell line, with RalA suppressing and RalB enhancing motility
[109].
Activating RAS mutations occur in a low percentage (~10%) of bladder cancers. Therefore, a
Ras-RalGEF mechanism may be less relevant for Ral activation in this cancer type.
Consistent with this possibility, a recent study found RalGAPα2 expression in normal
bladder urothelium, but reduced expression associated with advanced clinical stage and poor
patient survival [108]. Furthermore, genetic depletion of Ralgapα2 in mice did not cause
any apparent abnormalities but did enhance the invasive phenotype of chemically-induced
bladder tumors. Thus, loss of RalGAP function may be an important mechanism for Ral
activation in bladder cancer.
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Oncogenic KRAS and NRAS mutations occur in 45% and 8%, respectively, of colorectal
cancer (CRC) tumors. Ral signaling has been shown to be a critical regulator of the
anchorage-independent growth properties of CRC tumor cells [110]. Martin et al found that
RNAi-mediated suppression of RalA resulted in a decrease in soft agar colony growth while
loss of RalB had the opposite effect, leading to an enhancement of anchorage-independent
growth. They found that RalA and RalB modulated this phenotype by utilizing both
common and distinct effector proteins. Using Ral effector binding mutants that are
selectively uncoupled from Exo84, Sec5, or RalBP1, they showed that RalA required Exo84
and RalBP1 binding to promote the anchorage-independent growth of CRC cells.
Conversely, RalB required Sec5 and RalBP1 to suppress soft agar colony formation.
Intriguingly, loss of one Ral isoform was found to increase the activation of the other
isoform suggesting compensatory crosstalk between RalA and RalB. What specifically
mediates this crosstalk between RalA and RalB is unknown, but it could be through either
enhanced RalGEF accessibility for the remaining Ral protein or a downregulation of
RalGAP activity upon single Ral isoform depletion. Depletion of RalB has also been shown
to cause apoptosis in colorectal cancer cells [61].
6.3. Hepatocellular carcinoma
RAS mutations are rare (>2%) in hepatocellular carcinoma (HCC). RalA was found to be
significantly overactivated in hepatocellular carcinoma (HCC) cells and tissues compared to
nonmalignant samples. Suppression of RalA expression caused a significant decrease in the
viability and invasiveness of HCC cells. A role for RalB was not addressed. Finally, in a
transgenic mouse model for HCC (farnesoid X receptor–deficiency induced) elevated RalA-
GTP was detected in the liver tumors [111].
6.4. Lung adenocarcinoma
KRAS mutations are found in 30% of lung adenocarcinomas and several studies have
addressed the role of Ral in lung cancer. In one study, variable levels of RalA-GTP,
independent of KRAS mutation status, were detected in a panel of lung adenocarcinoma or
squamous carcinoma cell lines [112]. shRNA suppression of RalA expression in the KRAS
mutant A549 lung adenocarcinoma cell line reduced the proliferation and invasion in vitro.
In a second more comprehensive study, immunohistochemistry analyses of non-small cell
lung cancers (NSCLC), it was found that high RalA and RalB protein expression was
associated with poor survival. The levels of activated RalA but not RalB were higher in
KRAS-mutant NSCLC cell lines [113]. Depletion of RALA or RALB or both reduced
anchorage-dependent and –independent growth for either KRAS mutant and wild type cell
lines. Depletion of RALA, RALB, or both also impaired the tumorigenic growth of KRAS-
mutant NSCLC cells. Interesting, very limited analyses in this and another study suggested
mutation-selective involvement of Ral in NSCLC, where KRAS G12C mutant NSCLC cell
lines showed greater activation and/or dependence on Ral for growth [114].
In contrast to human lung tumor cell line studies, RalA and RalB were found to exhibit
redundant functions when assessed in mouse development and in a Kras G12D-driven
mouse model of lung adenocarcinoma [73]. Ralb deficient mice were viable with no overt
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phenotype whereas a Rala deficiency caused embryonic lethality that was further
exacerbated by a combined Ralb deficiency. Neither a Rala nor a Ralb deficiency impaired
Kras-driven lung tumor development. However, a combined loss of both Rala and Ralb
significantly reduced lung tumor development. These results suggest redundancy in RalA
and RalB function for tumor development. One possible explanation for this different
conclusion may be that the human lung tumor cell line studies addressed the role of Ral in
tumor maintenance whereas the mouse study addressed the role of Ral in tumor initiation
and progression.
6.5. Malignant peripheral nerve sheath tumors
Loss of the NF1 RasGAP, rather than RAS mutational activation, is seen in
neurofibromatosis type 1 and malignant peripheral nerve sheath tumors (MPNST) [115].
When compared with a nontransformed mouse Schwann cell line, RalA-GTP levels were
elevated in a panel of MPNST cell lines established from tumors that arose from a NF1- and
Tp53-deficient genetically-engineered mouse model. When evaluated in one cell line, RalA
suppression impaired proliferation and invasion in vitro and tumorigenic growth in vivo
[116]. RalA activation was also seen in human MPNST cell lines and tissue, and restoration
of NF1 GAP activity reduced RalA activity, indicating that this was associated with Ras
activation.
6.6. Melanoma
RAS mutations, predominantly NRAS, occur in 28% of skin cutaneous melanomas. With
BRAF mutations seen in 60% of melanomas in a non-overlapping frequency with RAS
mutations, activation of the canonical Raf-MEK-ERK mitogen-activated protein kinase
(MAPK) pathway alone may seem to be sufficient for Ras-driven melanoma growth.
However, analysis of Ral activation in a panel of human melanoma cells showed a
consistently high level of total and activated RalA, but not RalB, activation that was
independent of NRAS or BRAF mutation status [117]. Additionally, RalA and to a lesser
degree RalB are necessary for the tumorigenic growth of melanomas, also regardless of
BRAF and NRAS mutation status.
Studies using tumor suppressor Arf-deficient immortalized mouse melanocytes to
investigate the contributions of Ras downstream signaling to melanomagenesis also
indicated a role for Ral signaling [118]. Ectopic expression of the RalGEF Rgl2 engineered
to contain a membrane localization sequence (to mimic Ras activation of RalGEF) was
sufficient to promote the anchorage-independent growth and Matrigel invasion of these
melanocytes similar to that caused by oncogenic N-Ras. Surprisingly, in contrast, activated
BRAF V600E did not enhance proliferation or invasion. Finally, ectopic expression of a
dominant negative mutant of RalB that blocks RalGEF function partially impaired the
growth of NRAS-transformed melanocytes. Thus, together with the findings of Zipfel et al.
[117], Ral GTPases can act as drivers of melanoma cancer growth in both RAS wild type and
mutant cancer cells.
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One study has now revealed that Ral signaling has a role in ovarian cancer. Specifically,
higher levels of RalA activity was found in human tumor samples compared to benign
samples. Furthermore, depletion of RalA decreased proliferation and invasion of ovarian
cancer cell line OVCAR-5 in vitro and decreased tumor genesis [119].
6.8. Pancreatic ductal adenocarcinoma
A significant requirement for activated Ral signaling in pancreatic adenocarcinoma (PDAC)
cell line tumorigenic and invasive growth has been established. Human PDAC has a high
frequency or activating KRAS mutations and Ral activation is seen in both human tissue
samples and tumor cell lines [120-122]. Interestingly, activation of RalA was found at a
higher frequency than the activation of either ERK or AKT in PDAC cells, suggesting a
critical role for the RalGEF-Ral pathway downstream of oncogenic K-Ras.
Depletion of RalA and RalB via RNAi has elucidated roles for RalA in anchorage-
independent and tumorigenic growth and RalB in invasive and metastatic growth of PDAC
cells [122]. PDAC cells with stable RNAi depletion of RalA results in reduced subcutaneous
tumor formation upon injection into immune compromised mice. These same cells
expressing RalB RNAi do not form lung metastases post-injection into the tail-vein of nude
mice. In addition to playing a role in tumor initiation, RalA has also been shown to be
necessary for PDAC tumor maintenance. The use of inducible RNAi to stably deplete RalA
from established primary tumors resulted in regression of the tumor, indicating a necessity
for persistent RalA signaling in established PDAC tumors.
There is also recent evidence that active K-Ras signaling to RalB but not RalA plays a
critical role in the formation of invadopodia in PDAC cells [56]. Invadopodia are actin-rich
membrane protrusions that are known to be involved in the secretion of matrix
metalloproteases (MMP) during tumor cell invasion. RalB requires the ability to interact
with RalBP1 to mediate this process and RalBP1 itself is necessary for the formation of
invadopodia in PDAC cells. Surprisingly, the RhoGAP activity of RalBP1 is not necessary
for invadopodia formation while the ATPase activity is required. Why the ATPase activity is
necessary for RalBP1 to mediate invadopodia formation is unclear.
RalGEFs have also been found to play a role in PDAC. Rgl2 is overexpressed in PDAC
patient tumors and has been shown to be necessary for both the anchorage-independent and
invasive growth of PDAC tumor cells [123]. RNAi-mediated depletion of Rgl2 results in a
significant decrease in both RalA and RalB activation. Interestingly, expression of
constitutively active RalA could not rescue soft agar growth after the loss of Rgl2 indicating
that Rgl2 may have non-Ral regulatory functions or that the RalA interaction with Rgl2 is
critically important for the regulation of anchorage-independent growth. Rgl2 was found to
be co-localized with RalB but not RalA at the leading edge of migrating CFPac-1 PDAC
cells. Loss of Rgl2 results in a loss of RalB from the leading edge, perhaps giving insight
into how the migratory and invasive activity of PDAC cells relies on Rgl2/RalB signaling.
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Increased RalA-GTP levels were observed in the RAS wild type human prostate carcinoma
cell line PC3. Suppression of RalA did not impair tumor formation but did abolish bone
metastasis [124]. In contrast, suppression of RalB expression did not impair metastasis.
6.10. quamous cell carcinoma
Squamous cell carcinoma is the second most common type of skin cancer. Using an in vitro
model of Ras-induced human squamous cell carcinoma (SCC) of the skin, it was found that
RalA suppressed rather than promoted progression [125]. Suppression of RalA but not RalB
stimulated the progression of HRAS-transformed human keratinocytes to a more invasive
state.
In contrast to the in vitro observations, different roles for Ral were observed in a mouse
model of carcinogen-induced SCC [73]. Single application of the mutagen DMBA, followed
by repeated applications of phorbol ester 12-O-tetradecanoylphorbol 13-acetate (TPA)
causes Hras mutation and the development of benign papillomas, with a subset progressing
to SCC. Neither a Rala nor a Ralb deficiency impaired papilloma development. As
described above for Kras-driven lung adenocarcinoma formation, only combined loss of
both Rala and Ralb significantly reduced papilloma development. Genetic ablation of
Ralgds in this same carcinogenesis model also significantly reduced tumor incidence, size,
and progression [126].
7. Conclusions and Future Prospects
Ral GTPase signaling has emerged as being critically important in both normal and
neoplastic cell physiology. Over the last two and a half decades we have learned a great deal
about how Ral proteins regulate many biological processes. From these studies one of the
most striking observations has been the very distinct functions observed for RalA and RalB
despite similar structural and biochemical properties and shared effector utilization. Do
these distinct functions simply reflect to spatially distinct interactions with the same set of
effectors or are their Ral isoform selective effectors that remain to be discovered. Only
recently have RalGAPs been discovered and much more remains to be learned regarding
their roles in regulation of Ral activity and signaling. With increasing evidence for key roles
for Ral GTPases as drivers in cancer growth, it will be important to identify pharmacologic
approaches for targeting aberrant Ral function for cancer treatment. Like Ras, Ral proteins
are not tractable therapeutic targets, although recent progress in the identification of direct
Ras binders suggests that small GTPases may yet be targeted directly. If not, indirect
approaches need to be explored. With kinases implicated as downstream effectors or key
regulators of Ral GTPases, can these be exploited for anti-Ral drug development? In
summary, with more still to be learned regarding Ral function, it is quite certain that there
will be more than 15 minutes remaining in their fame.
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CAAX cysteine-aliphatic-aliphatic-terminal amino acid
DMBA 7,12-dimethylbenz[α]anthracene
EGF epidermal growth factor
EH Eps homology
ER endoplasmic reticulum
GAP GTPase activating protein
GEF guanine nucleotide exchange factor
ICMT isoprenylcysteine carboxyl methyltransferase
NSCLC non-small cell lung cancer
PDAC pancreatic ductal adenocarcinoma
PH pleckstrin homology domain
PKA protein kinase A
PKC protein kinase C
RA Ras-association domain
RBD Ral-binding domain
RCE1 Ras converting enzyme 1
REM Ras exchanger motif
SI/II SwitchI/II
SCC squamous cell carcinoma
SH3 Src homology 3 domain
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• Ral proteins are members of the Ras superfamily of small GTPases
• Ral functions as GTP-GDP regulated binary on-off switch in signaling
• Ral proteins are key downstream effectors of Ras oncoprotein-mediated
oncogenesis
• Ral regulates vesicular transport and actin organization
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Evolutionary conservation of Ral small GTPases. A. Human and invertebrate Ral orthologs
exhibit strong sequence identity. The RalA and RalB isoforms are found in all vertebrate
species [17]. There is one Ral ortholog in C. elegans (Ce) and D. melanogaster (Dm).
Overall sequence identity was determined by CLUSTALW multiple sequence alignment. B.
Ral GTPases are members of the Ras branch of the Ras superfamily. Shown here is a
comparison with the four Ras proteins and representative members of the Ras family. The
dendrogram was generated by CLUSTALW multiple sequence alignment. C. Dendrogram
showing sequence relationship of human and invertebrate Ral proteins. D. Ral domain
structure. Human RalA and RalB G domains (12-176) shares 88% sequence identity and
contain the SI and SII domains that change in conformation during GDP-GTP cycling and
are involved in interaction with regulators and effectors. The switch regions are conserved
between human Ral proteins and Drosophila Ral and differ by a single residue in each
switch in C. elegans Ral (identical residues indicated in blue text). The hypervariable (HV)
C-terminus (50% identity) consists of the membrane targeting region and contains key post-
translational phosphorylation sites that regulate Ral subcellular localization and effector
interaction. Multiple sequence alignment was done by ClustalW analyses and domain
topology by SMART analyses. Numbers correspond to the human Ral amino acid
sequences.
Gentry et al. Page 26























Gentry et al. Page 27






















Regulators of the Ral GDP-GTP cycle. A. Regulation of Ral GDP-GTP cycling. Ral-
selective GEFs and GAPs accelerate the low intrinsic exchange and GTP hydrolysis
activities to promote formation of active GTP-bound and inactive GDP-bound Ral. B. The
RalGEFs are highly conserved across species. All RalGEFs contain a CDC25 homology
domain, which is responsible for catalytic activity. There are four human isoforms of
RalGEF that contain Ras association (RA) domain. These isoforms also contain a Ras
exchanger motif (REM) that likely stabilizes the CDC25 homology domain and is essential
for RalGEF catalytic activity. There is one homolog in C. elegans and two in Drosophila.
The RalGEF homolog in C. elegans is most similar to RalGDS. The RalGPS RalGEFs lack
a REM domain and do not associate with Ras, but instead contain a pleckstrin homology
(PH) domain. RGL4 contains a CDC25 homology domain, but lacks a REM, RA or PH
domain. C. The RalGAPs are heterodimeric complexes formed by either a RalGAPα1 or
RalGAPα2 catalytic subunit with the regulatory RalGAPβ subunit. The RalGAPβ subunit
serves to regulate the catalytic activity of the RalGAPα subunits, similar to TSC1 regulation
of TSC2. Percentages indicate sequence identity with the RalGAPα1 catalytic domain.
Orthologs of the human RalGAPα and RalGAPβ subunits are present in C. elegans and
Drosophila. Multiple sequence alignment and sequence identity was determined by
ClustalW analyses and domain topology by SMART analyses.
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Ral effectors and effector functions. Active Ral can bind to a variety of downstream
effectors and modulate numerous cellular activities. RalBP1 acts as a RhoGAP as well as a
scaffold for other proteins that regulate endocytosis and other cellular processes. Ral
association with Sec5 or Exo84 can regulate exocyst-dependent and –independent processes.
Other effector processes include regulation of cell cycle progression through PLD1-
dependent cytokinesis and cytoskeletal changes through filamin A, IP3 signaling through
PLCδ1, and gene transcription through ZONAB. Ral activation also stimulates signaling
pathways that lead to the activation of various transcription factors (TF), stimulating gene
expression.
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Regulation of Ral subcellular localization and membrane association. CAAX motif-signaled
posttranslational modifications. Ral is geranylgeranylated by GGTase-1 on the first cysteine
residue of the CAAX (RalA: CCIL; RalB: CCLL). By the canonical CAAX processing
pathway, Ral is then modified at the endoplasmic reticulum (ER) by Ras converting enzyme
(Rce1) which cleaves between the two cysteine residues. Isoprenyl cysteine carboxyl
methyltransferase (ICMT) then catalyzes methylation of the isoprenylated free cysteine
residue, facilitating recruitment to the plasma membrane. A second non-canonical pathway
has been described by which Ral is palmitoylated at the cysteine residue at the A1 position
by Golgi-associated protein acetyltransferase (PAT) after geranylgeranylation. Palmitate
addition is reversible and depalmitoylation is catalyzed by acylprotein thioesterase (APT).
Whether this double lipid modified form is associated with a different membrane
compartment has not been determined. Ral subcellular localization is also regulated by a
dynamic and reversible protein kinase (PK)-mediated phosphorylation and protein
phosphatase (PP)-mediated dephosphorylation cycle. RalA and RalB possess distinct C-
terminal phosphorylation sites for different protein kinases (PK). Phosphorylation causes
dissociation from the plasma membrane and translocation to specific endomembrane
compartments, resulting in a switch in effector (E) interaction.
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EGFR signaling toggles C. elegans developmental output by effector switching. The C.
elegans Ras ortholog (LET-60) can interact with orthologs of human Raf (LIN-45) and
RalGEF (RGL-1). The nearby anchor cell (AC) secretes EGF/LIN-3, creating a
concentration gradient, inducing vulval precursor cell (VPC) development. This
concentration gradient, in combination with sequential induction, patterns vulval cell fates.
Active pro-1° signaling is shown in blue, with active pro-2° signaling shown in red, and
quenched signaling is in gray. In presumptive 1° cells, typically P6.p, EGF activates Ras to
utilize Raf to promote 1° cell fate. Pro-2° signaling through Notch is quenched.
RGL-1→RAL-1 pro-2° quenching is based on RAL-1 exclusion from presumptive 1° cells.
Additionally, presumptive 1° cells express and secrete notch ligand (DSL; Delta/Serrate/
LAG-2) that then induces neighboring vulval precursor cells via the Notch/LIN-12 receptor
to assume a 2° fate. In presumptive 2° cells, Notch induces expression of an ERK MAPK
phosphatase, and other 2°-specific proteins to quench the Raf pro-1° signal. EGF activates
Ras to utilize the RGL-1 RalGEF effector to promote 2° fate.
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